Business Overview: Pro-Dex, Inc. (NASDAQ: PDEX)

---

Executive Summary

Pro-Dex designs, develops, and manufactures autoclavable, battery-powered and electric surgical drivers and shavers for the orthopedic, thoracic, and craniomaxillofacial (CMF) markets, operating almost entirely as a proprietary-design partner under exclusive development and supply agreements rather than a branded consumer medical device maker. In February 2026 it diversified into aerospace and defense by acquiring Advanced Precision Machining (APM), a precision-machining business in Costa Mesa, California that is an ITAR-registered government prime contractor.

FY2026 revenue grew to $77.5 million, driven by medical device sales climbing to $62.1 million, but the business carries extreme customer concentration: its top three customers were 92% of sales, with a single customer alone representing 78%. That customer's supply agreement was recently extended through calendar 2028 — the explicit rationale management gave for the APM acquisition, suggesting diversification is as much a defensive necessity as a growth strategy.

---

1. Core Business Model & How They Work

   OEM Medical Device Customers (top 3 = 92% of sales,
   largest single customer = 78%)
                        |
                        v
   +------------------------------------------------+
   |  Exclusive Development & Supply Agreements       |
   |  (proprietary torque-limiting tech, custom devices)|
   +----------------------+-----------------------------+
                          |
          +---------------+----------------+
          v                                v
   +------------------+          +---------------------+
   |  Design & Mfg      |          |  Repairs / NRE &     |
   |  (Irvine machining, |          |  Prototype Billing   |
   |  Tustin assembly)   |          +---------------------+
   +------------------+
          |
          v
   Surgical Drivers/Shavers -> Orthopedic, Thoracic,
   CMF Surgical Markets

   [New, 2026]: APM (Costa Mesa) -> Precision Machined
   Parts -> Aerospace & Defense (ITAR Prime Contractor)

Pro-Dex's core business is developing proprietary, patented surgical devices under long-term exclusive agreements with a small number of large medical device OEM customers, who then sell the finished devices under their own brands. Revenue comes from device sales, non-recurring engineering and prototype billing for new designs, and repair services for devices already in the field — though repair revenue is now declining as the largest customer shifts to a next-generation handpiece that Pro-Dex itself likely also supplies.

---

2. Business Segments

Pro-Dex reports one reportable operating segment. However, following the February 2026 APM acquisition, the business now spans two distinct end markets worth describing separately:

                       Pro-Dex, Inc.
                            |
        +-------------------+-------------------+
        |                                       |
   Medical Devices                    Aerospace & Defense
   (Irvine/Tustin, CA)                  (APM, Costa Mesa, CA --
   Surgical drivers/shavers for          acquired Feb. 2026)
   ortho/thoracic/CMF OEMs               Precision machined parts,
                                          ITAR Prime Contractor

---

3. Product Portfolio

---

4. Competitive Landscape

Pro-Dex describes its market as intensely competitive, facing rivals that are "often larger, with more name recognition and resources" in the surgical device design and manufacturing space, as well as — notably — its own customers' in-house development and manufacturing teams, which represent an ever-present insourcing risk. In its new aerospace and defense line via APM, Pro-Dex enters a highly regulated, ITAR-governed market where competition is shaped as much by certifications (AS9100D, ISO 9001:2015, Joint Certification Program) as by price.

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

• Patented adaptive torque-limiting technology and proprietary sealing solutions that are embedded in exclusive, long-term development and supply agreements with OEM customers.
• The largest customer's supply agreement was recently extended through calendar 2028, providing multi-year revenue visibility.
• ISO 13485:2016 certification at both Irvine and Tustin facilities, plus FDA establishment registration, representing regulatory barriers new entrants must clear.
• The APM acquisition adds ITAR-registered Prime Contractor status and AS9100D/ISO 9001:2015 certification, opening a largely uncorrelated aerospace/defense revenue stream.

Risks

• Extreme customer concentration: the top three customers are 92% of FY2026 sales, with one customer alone at 78% — a level of dependence that makes Pro-Dex's entire business essentially hostage to one relationship.
• Declining repair revenue ($12.5M, down from $18.6M) as the largest customer transitions to a next-generation handpiece.
• Falling backlog ($32.9M at FY2026 year-end, down from $50.4M), attributed to timing but worth monitoring.
• Competes against customers' own in-house development and manufacturing teams, a structural insourcing threat unique to contract-design businesses.
• New tariff costs from suppliers are being passed through, with some but not all absorbed cost passed on to Pro-Dex's own customers.
• Single-source dependence on specialized components from suppliers like Portescap, Fischer Connectors, and Tadiran Batteries.
• The APM acquisition adds new regulatory complexity (ITAR, government contracting) that is unfamiliar territory for a historically medical-device-focused company.

---

6. Financial Overview

---

7. Summary Conclusion

Pro-Dex has built real, patent-protected technical capability in surgical device design, reinforced by multi-year exclusive supply agreements and strong regulatory certifications — but its business is dangerously concentrated in a single customer relationship that represents the large majority of revenue. The recent contract extension through 2028 buys stability, but it also underscores just how much the entire enterprise rests on one counterparty's continued commitment.

The February 2026 APM acquisition is a clear, deliberate move to diversify away from that concentration risk into aerospace and defense, a largely uncorrelated end market — a sensible strategic hedge, though it is too early to know whether Pro-Dex can execute as well in ITAR-governed precision machining as it has in medical device design.